In 55 placebo-controlled trials covering 106,395 people, the risk ratio was 1.46 for gallstones and 2.19 for reflux [2]. That is about two extra gallstone cases and four extra reflux cases per thousand. The authors found less evidence of a change in other gastrointestinal or biliary risks. The separate review of cough during GLP-1 treatment covers a symptom outside that analysis. Reflux and cough can have other causes.
In a phase 2b trial in China, gastrointestinal events occurred in 51.9% of participants on weekly semaglutide 1 mg and 81.8% to 87.3% of participants across the bofanglutide groups. Most were grade 1 or 2[3]. These rates describe the drugs and regimens tested in adults with type 2 diabetes.
A separate records study of tirzepatide users with obesity and heart failure with preserved ejection fraction found a lower hazard of recorded nausea and vomiting in men than women (hazard ratio 0.50, 95% CI 0.37 to 0.67)[4]. The review of side-effect differences by sex discusses the limits of diagnosis codes. The estimate applies to this matched cohort.
The matched study compared a composite of severe events. The analysis of tirzepatide’s costs and outcomes covers a separate question about value. The severe-event comparison cannot tell you how likely you are to experience everyday nausea on either drug.
What was compared
A new-user, active-comparator cohort study identified adults with type 2 diabetes starting dulaglutide, semaglutide or tirzepatide. The window ran from January 2019 to August 2024. It built three pairwise comparisons, propensity-matched 1:1 within each [1].
That produced 65,238 matched pairs for semaglutide against dulaglutide, 20,893 for tirzepatide against dulaglutide, and 46,620 for tirzepatide against semaglutide. The primary outcome was a composite of acute pancreatitis, biliary disease, bowel obstruction, gastroparesis and severe constipation.
How the severe-event estimates compared
Semaglutide against dulaglutide gave 0.96 (95% CI 0.87 to 1.06). Tirzepatide against dulaglutide gave 0.96 (95% CI 0.77 to 1.20). Tirzepatide against semaglutide gave 1.07 (95% CI 0.90 to 1.26).
All three confidence intervals include 1.0. For tirzepatide versus semaglutide, the interval also includes estimates consistent with lower or higher risk. The study leaves uncertainty about the size and direction of any difference.
Our guide to rash during GLP-1 treatment examines the evidence for skin reactions. The analysis of semaglutide trial discontinuation instead examines stopping because of adverse events. The studies report different outcomes, so check what each counted.
Set against what the two cost
Across the 158 injected semaglutide figures and 159 injected tirzepatide figures recorded here, the median billed rates are $186 and $269. That is a difference of $83, or $996 over a year. Roster read November 2026.
These are prices for published offers. They do not tell you which drug you will tolerate better. Discuss individual risks with your prescriber.
The comparison a buyer can actually make
The monthly price guide explains which charges go into the estimate. If your dose changes, the guide to pricing at higher doses explains why a starting quote can understate later costs. Ask the provider for the refill price at the dose on your prescription.